MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10781552211060479

Медицинская библиотека · Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021

High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation.

Hawks Kelly G, Fegley Amanda, Sabo Roy T, Roberts Catherine H, Toor Amir A

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Cytomegalovirus (CMV) is one of the most common and clinically significant viral infections following allogeneic hematopoietic cell transplantation (HCT). Currently available options for CMV prophylaxis and treatment present challenges related to side effects and cost.

METHODS

In this retrospective medical record review, the incidence of clinically significant CMV infection (CMV disease or reactivation requiring preemptive treatment) following allogeneic HCT was compared in patients receiving valacyclovir 1 g three times daily versus acyclovir 400 mg every 12 h for viral prophylaxis.

RESULTS

Forty-five patients who received valacyclovir were matched based on propensity scoring to 35 patients who received acyclovir. All patients received reduced-intensity conditioning regimens containing anti-thymocyte globulin. Clinically significant CMV infection by day + 180 was lower in the valacyclovir group compared to the acyclovir group (18% vs. 57%, p = 0.0004). Patients receiving valacyclovir prophylaxis also had less severe infection evidenced by a reduction in CMV disease, lower peak CMV titers, delayed CMV reactivation, and less secondary neutropenia.

CONCLUSION

Prospective evaluation of valacyclovir 1 g three times daily for viral prophylaxis following allogeneic HCT is warranted. Due to valacyclovir's favorable toxicity profile and affordable cost, it has the potential to benefit patients on a broad scale as an option for CMV prophylaxis.

Для цитирования: Hawks Kelly G, Fegley Amanda, Sabo Roy T, Roberts Catherine H, Toor Amir A. High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2021. DOI: 10.1177/10781552211060479.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.